135 related articles for article (PubMed ID: 27907860)
21. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells.
Cao N; Cheng D; Zou S; Ai H; Gao J; Shuai X
Biomaterials; 2011 Mar; 32(8):2222-32. PubMed ID: 21186059
[TBL] [Abstract][Full Text] [Related]
22. Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy.
Sharma H; Sen S; Lo Muzio L; Mariggiò A; Singh N
Cancer Biol Ther; 2005 Jul; 4(7):720-7. PubMed ID: 15917659
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines.
Sartorius UA; Krammer PH
Int J Cancer; 2002 Feb; 97(5):584-92. PubMed ID: 11807782
[TBL] [Abstract][Full Text] [Related]
24. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
[TBL] [Abstract][Full Text] [Related]
25. Monitoring drug induced apoptosis and treatment sensitivity in non-small cell lung carcinoma using dielectrophoresis.
Taruvai Kalyana Kumar R; Liu S; Minna JD; Prasad S
Biochim Biophys Acta; 2016 Sep; 1860(9):1877-83. PubMed ID: 27262539
[TBL] [Abstract][Full Text] [Related]
26. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.
Hu Y; Bebb G; Tan S; Ng R; Yan H; Sartor JR; Mayer LD; Bally MB
Clin Cancer Res; 2004 Nov; 10(22):7662-70. PubMed ID: 15569999
[TBL] [Abstract][Full Text] [Related]
27. Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines.
Tahir SK; Wass J; Joseph MK; Devanarayan V; Hessler P; Zhang H; Elmore SW; Kroeger PE; Tse C; Rosenberg SH; Anderson MG
Mol Cancer Ther; 2010 Mar; 9(3):545-57. PubMed ID: 20179162
[TBL] [Abstract][Full Text] [Related]
28. Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors.
Mita M; Gordon M; Rosen L; Kapoor N; Choy G; Redkar S; Taverna P; Oganesian A; Sahai A; Azab M; Bristow R; Tolcher AW
Cancer Chemother Pharmacol; 2014 Jul; 74(1):195-204. PubMed ID: 24849582
[TBL] [Abstract][Full Text] [Related]
29. PEGylated anticancer-carbon nanotubes complex targeting mitochondria of lung cancer cells.
Kim SW; Kyung Lee Y; Yeon Lee J; Hee Hong J; Khang D
Nanotechnology; 2017 Nov; 28(46):465102. PubMed ID: 29053471
[TBL] [Abstract][Full Text] [Related]
30. In vitro evaluation of antisense oligonucleotide functionalized core-shell nanoparticles loaded with α-tocopherol succinate.
Kilicay E; Karahaliloglu Z; Alpaslan P; Hazer B; Denkbas EB
J Biomater Sci Polym Ed; 2017 Oct; 28(15):1762-1785. PubMed ID: 28696185
[TBL] [Abstract][Full Text] [Related]
31. Lactate-induced MRP1 expression contributes to metabolism-based etoposide resistance in non-small cell lung cancer cells.
Dong Q; Zhou C; Ren H; Zhang Z; Cheng F; Xiong Z; Chen C; Yang J; Gao J; Zhang Y; Xu L; Fang J; Cao Y; Wei H; Wu Z
Cell Commun Signal; 2020 Oct; 18(1):167. PubMed ID: 33097055
[TBL] [Abstract][Full Text] [Related]
32. A strategy using mesoporous polymer nanospheres as nanocarriers of Bcl-2 siRNA towards breast cancer therapy.
Wu X; Zheng Y; Yang D; Chen T; Feng B; Weng J; Wang J; Zhang K; Zhang X
J Mater Chem B; 2019 Jan; 7(3):477-487. PubMed ID: 32254735
[TBL] [Abstract][Full Text] [Related]
33. Enhanced efficacy of local etoposide delivery by poly(ether-anhydride) particles against small cell lung cancer in vivo.
Tang BC; Fu J; Watkins DN; Hanes J
Biomaterials; 2010 Jan; 31(2):339-44. PubMed ID: 19796810
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells.
Dos Santos Ferreira AC; Fernandes RA; Kwee JK; Klumb CE
J Cancer Res Clin Oncol; 2012 Feb; 138(2):317-25. PubMed ID: 22131152
[TBL] [Abstract][Full Text] [Related]
35. Well-Defined Redox-Sensitive Polyethene Glycol-Paclitaxel Prodrug Conjugate for Tumor-Specific Delivery of Paclitaxel Using Octreotide for Tumor Targeting.
Yin T; Wu Q; Wang L; Yin L; Zhou J; Huo M
Mol Pharm; 2015 Aug; 12(8):3020-31. PubMed ID: 26086430
[TBL] [Abstract][Full Text] [Related]
36. Controlled release of NFkappaB decoy oligonucleotides from biodegradable polymer microparticles.
Zhu X; Lu L; Currier BL; Windebank AJ; Yaszemski MJ
Biomaterials; 2002 Jul; 23(13):2683-92. PubMed ID: 12059017
[TBL] [Abstract][Full Text] [Related]
37. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer.
Herbst RS; Frankel SR
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4245s-4248s. PubMed ID: 15217967
[TBL] [Abstract][Full Text] [Related]
38. T7 Peptide-Conjugated Lipid Nanoparticles for Dual Modulation of Bcl-2 and Akt-1 in Lung and Cervical Carcinomas.
Cheng X; Yu D; Cheng G; Yung BC; Liu Y; Li H; Kang C; Fang X; Tian S; Zhou X; Liu Q; Lee RJ
Mol Pharm; 2018 Oct; 15(10):4722-4732. PubMed ID: 30138565
[TBL] [Abstract][Full Text] [Related]
39. D-α-tocopherol polyethylene glycol succinate-based derivative nanoparticles as a novel carrier for paclitaxel delivery.
Wu Y; Chu Q; Tan S; Zhuang X; Bao Y; Wu T; Zhang Z
Int J Nanomedicine; 2015; 10():5219-35. PubMed ID: 26316751
[TBL] [Abstract][Full Text] [Related]
40. An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma.
Shen M; Gong F; Pang P; Zhu K; Meng X; Wu C; Wang J; Shan H; Shuai X
Int J Nanomedicine; 2012; 7():3319-32. PubMed ID: 22802690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
